Menarini Group Unveils New Insights on ELZONRIS® at ASH Annual Meeting Menarini Group announces significant new findings on ELZONRIS® at the upcoming ASH Annual Meeting, aiding patients with BPDCN.

Menarini Group Unveils New Insights on ELZONRIS® at ASH Annual Meeting #Italy #Menarini #Florence #BPDCN #ELZONRIS

Menarini Group Presents New Data on ELZONRIS at ASH 2025 Annual Meeting Menarini Group and Stemline Therapeutics reveal new findings regarding ELZONRIS® data at the 67th ASH Annual Meeting, highlighting innovative treatments for BPDCN.

Menarini Group Presents New Data on ELZONRIS at ASH 2025 Annual Meeting #USA #Orlando #Menarini_Group #BPDCN #ELZONRIS

Menarini Group Unveils New Insights on ELZONRIS at ASH 2025 Annual Meeting Menarini Group and Stemline Therapeutics will present essential findings on ELZONRIS at ASH's Annual Meeting, emphasizing its potential in treating aggressive blood cancers.

Menarini Group Unveils New Insights on ELZONRIS at ASH 2025 Annual Meeting #USA #Orlando #Menarini #BPDCN #ELZONRIS

Menarini Group Unveils Promising Data for ELZONRIS® at ASH Annual Meeting Menarini Group announces significant results for ELZONRIS® at the upcoming ASH Annual Meeting, highlighting new treatment options for patients with BPDCN.

Menarini Group Unveils Promising Data for ELZONRIS® at ASH Annual Meeting #USA #Orlando #Menarini_Group #BPDCN #ELZONRIS

Menarini Group Unveils Promising Findings on ELZONRIS for BPDCN at ASH Meeting Key new findings on ELZONRIS treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) to be showcased at the 67th American Society of Hematology Annual Meeting in December 2025.

Menarini Group Unveils Promising Findings on ELZONRIS for BPDCN at ASH Meeting #Italy #Florence #Menarini_Group #BPDCN #ELZONRIS